Dr. Petrylak on a study of neoadjuvant carboplatin in BRCA+ prostate cancer

In this video, Daniel P. Petrylak, MD, discusses the ongoing phase 2 SWOG S2210 trial (NCT05806515) of neoadjuvant carboplatin in patients with localized, high-risk prostate cancer and germline BRCA1/2 mutations. Petrylak is professor of medicine (medical oncology) and of urology at Yale School of Medicine and chief of genitourinary oncology at Yale Cancer Center, New Haven, Connecticut.

Video Transcript:

Could you describe the design and key end points for this study?

The study is designed to evaluate high-risk patients. These patients have T3 or T4 disease, a PSA of greater than 20, a Gleason score of 8 or higher, and they have to have a BRCA1 or BRCA2 mutation. These patients will then undergo chemotherapy with carboplatin in addition to androgen deprivation therapy, and then they will have radical prostatectomy as a way to define whether there is a pathological tissue response, which is the primary end point for this particular trial.

What are the potential implications of this study?

This is a phase 2 study. So, this is basically designed to look at activity in the complete and partial response rates to chemotherapy. If this does show some significant activity, then this potentially could go into a phase 3 trial. As I mentioned earlier, we know that the BRCA1/BRCA2 patients tend to have a poorer prognosis overall than the general patients with the wild-type phenotype. This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles.

This transcription has been edited for clarity.